Blister pack with dollars instead of pills In the midst of a pandemic, the drug industry is likely at least in the short term to see a boost to its bottom lines. (Photo: Shutterstock)

Just as other products have seen sales and profits go through the roof as people stocked up on goods in response to lockdowns, pharmaceutical company Eli Lilly has not only beat quarterly estimates but also boosted its profit forecast for 2020 as customers have stocked up on such drugs as its diabetes drug Trulicity and psoriasis drug Taltz.

According to a Reuters report, the company did warn that the phenomenon would likely reverse over the course of the year and it could still be hit with a negative impact to drug prices given the toll coronavirus is taking on the economy.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employer-Paid